erlotinib hydrochloride has been researched along with Hearing Loss, Sensorineural in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Halpin, C; Harris, GJ; McClatchey, AI; O'Donnell, CC; Plotkin, SR; Singh, MA | 1 |
| Evans, TR; Kalofonos, HP; Koutras, AK; Makatsoris, T; Mastronikolis, NS; Papadeas, ES | 1 |
| Barker, FG; Batchelor, TT; Halpin, C; Loeffler, JS; McKenna, MJ; Plotkin, SR | 1 |
3 other study(ies) available for erlotinib hydrochloride and Hearing Loss, Sensorineural
| Article | Year |
|---|---|
Audiologic and radiographic response of NF2-related vestibular schwannoma to erlotinib therapy.
Topics: Audiometry, Pure-Tone; Auditory Threshold; Cochlear Implantation; Combined Modality Therapy; Ear Neoplasms; Erlotinib Hydrochloride; Hearing Loss, Sensorineural; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Neurofibromatosis 2; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome; Vestibular Diseases | 2008 |
Irreversible ototoxicity associated with the use of erlotinib in a patient with pancreatic cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Dizziness; ErbB Receptors; Erlotinib Hydrochloride; Fatal Outcome; Female; Hearing; Hearing Loss, Sensorineural; Humans; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quality of Life; Quinazolines; Tinnitus; Treatment Failure | 2008 |
Erlotinib for progressive vestibular schwannoma in neurofibromatosis 2 patients.
Topics: Adolescent; Adult; Antineoplastic Agents; Audiometry, Pure-Tone; Disease Progression; Erlotinib Hydrochloride; Female; Hearing Loss, Sensorineural; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Neurofibromatosis 2; Neuroma, Acoustic; Quinazolines; Speech Perception; Treatment Outcome; Young Adult | 2010 |